Want to see CRSP full AI Analyst Report?
CRSP Stock Chart & Stats
$46.54
-$0.99(-2.08%)
At close: 4:00 PM EDT
$46.54
-$0.99(-2.08%)
Day’s Range― - ―
52-Week Range$44.12 - $78.48
Previous CloseN/A
Volume1.39M
Average Volume (3M)1.68M
Market Cap
$4.59B
Enterprise Value$2.91K
Total Cash (Recent Filing)$2.44B
Total Debt (Recent Filing)$787.64M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Aug 10, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.22
Shares Outstanding96,448,790
10 Day Avg. Volume1,726,236
30 Day Avg. Volume1,677,481
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.45
Price to Sales (P/S)1343.50
P/FCF Ratio-13.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$72.53Price Target Upside55.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-4.88
Revenue Forecast (FY)$39.11M
Bulls Say, Bears Say
Bulls Say
Strategic Partnership (Vertex/exa-cel)The Vertex collaboration creates a durable, de-risking revenue pathway: milestone payments and shared commercial economics can fund R&D and operations while Vertex’s commercialization expertise accelerates market access for exa-cel, reducing single-company commercialization risk over the next several quarters.
Sizable Equity BaseA sizable equity base relative to debt provides financial cushion and flexibility to support ongoing clinical programs and near-term operating needs. This buffer reduces immediate refinancing urgency and helps sustain multi-quarter R&D investment while clinical readouts progress.
Improved Liquidity Via Financings And Governance ActionsThe sizable convertible offering and shareholder-approved capital authority materially bolster liquidity and funding optionality. Enhanced liquidity supports execution of costly trials and commercialization steps over the medium term, improving the company’s ability to hit clinical and regulatory milestones.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow mean the company must rely on external financing or partnership payments to sustain operations. Over months this elevates execution risk, ties strategy to financing windows, and can force program prioritization if funding markets tighten.
Large, Volatile Losses And Negative MarginsDeep and volatile losses indicate the business is far from break-even; negative margins limit retained earnings and heighten sensitivity to trial or commercial setbacks. Sustained unprofitability increases dependence on partners/financings and constrains long-term shareholder returns.
Rising Leverage And Debt Increase RiskMaterially higher leverage raises fixed obligations and financial fragility during a capital-intensive clinical development cycle. Increased debt (including convertibles) may limit strategic flexibility, elevate refinancing risk, and introduce dilution or costly covenant constraints over the next several quarters.
Crispr Therapeutics AG News
CRSP FAQ
What was Crispr Therapeutics’s price range in the past 12 months?
Crispr Therapeutics lowest stock price was $44.12 and its highest was $78.48 in the past 12 months.
What is Crispr Therapeutics’s market cap?
Crispr Therapeutics’s market cap is $4.59B.
When is Crispr Therapeutics’s upcoming earnings report date?
Crispr Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 9 days.
How were Crispr Therapeutics’s earnings last quarter?
Crispr Therapeutics released its earnings results on May 04, 2026. The company reported -$1.28 earnings per share for the quarter, missing the consensus estimate of -$1.218 by -$0.062.
Is Crispr Therapeutics overvalued?
According to Wall Street analysts Crispr Therapeutics’s price is currently Undervalued.
Does Crispr Therapeutics pay dividends?
Crispr Therapeutics does not currently pay dividends.
What is Crispr Therapeutics’s EPS estimate?
Crispr Therapeutics’s EPS estimate is -1.2.
How many shares outstanding does Crispr Therapeutics have?
Crispr Therapeutics has 96,448,790 shares outstanding.
What happened to Crispr Therapeutics’s price movement after its last earnings report?
Crispr Therapeutics reported an EPS of -$1.28 in its last earnings report, missing expectations of -$1.218. Following the earnings report the stock price went down -2.24%.
Which hedge fund is a major shareholder of Crispr Therapeutics?
Currently, no hedge funds are holding shares in CRSP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crispr Therapeutics AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$72.53 (55.85% Upside)
$72.53 (55.85% Upside)
Blogger Sentiment
Bullish
CRSP Sentiment 88%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 668.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.84%
Trailing 12-Months
Company Description
Crispr Therapeutics
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
CRSP Stock 12 Month Forecast
Average Price Target
$72.53
▲(55.85% Upside)
Technical Analysis
Intellia Therapeutics
―
Apellis Pharmaceuticals
―
Beam Therapeutics
―
Legend Biotech
―
Kymera Therapeutics
―
Ownership Overview
2.54% Insiders
13.62% Mutual Funds
2.53% Other Institutional Investors
62.14% Public Companies and Individual Investors